Skip Navigation

Leading articles

From the Current Issue: August 1 2008; 62 (2) [Table of Contents]

Hong Zhang
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza
J. Antimicrob. Chemother. 2008. 62:219-223. [Abstract] [Full Text] [PDF]

Nidhi A. Singh and Nancy Reau
Management of hepatitis B virus
J. Antimicrob. Chemother. 2008. 62:224-228. [Abstract] [Full Text] [PDF]

From Past Issues:

Vincent Soriano, Alan S. Perelson, and Fabien Zoulim
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
J. Antimicrob. Chemother. 2008. 62:1-4. [Abstract] [Full Text] [PDF]

Linos Vandekerckhove, Chris Verhofstede, and Dirk Vogelaers
Maraviroc: integration of a new antiretroviral drug class into clinical practice
J. Antimicrob. Chemother. 2008. 61:1187-1190. [Abstract] [Full Text] [PDF]

Benedicte Roquebert and Anne-Genevieve Marcelin
The involvement of HIV-1 RNAse H in resistance to nucleoside analogues
J. Antimicrob. Chemother. 2008. 61:973-975. [Abstract] [Full Text] [PDF]

I. M. Gould
Antibiotic policies to control hospital-acquired infection
J. Antimicrob. Chemother. 2008. 61:763-765. [Abstract] [Full Text] [PDF]

Julie Sheldon and Vincent Soriano
Hepatitis B virus escape mutants induced by antiviral therapy
J. Antimicrob. Chemother. 2008. 61:766-768. [Abstract] [Full Text] [PDF]

Robert W. Burgoyne and Darrell H. S. Tan
Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
J. Antimicrob. Chemother. 2008. 61:469-473. [Abstract] [Full Text] [PDF]

Neil Woodford
Successful, multiresistant bacterial clones
J. Antimicrob. Chemother. 2008. 61:233-234. [Abstract] [Full Text] [PDF]

Johan W. Mouton, Ursula Theuretzbacher, William A. Craig, Paul M. Tulkens, Hartmut Derendorf, and Otto Cars
Tissue concentrations: do we ever learn?
J. Antimicrob. Chemother. 2008. 61:235-237. [Abstract] [Full Text] [PDF]

Katherine Samaras
Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
J. Antimicrob. Chemother. 2008. 61:238-245. [Abstract] [Full Text] [PDF]

B. Cherie Millar, Bernard D. Prendergast, and John E. Moore
Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis
J. Antimicrob. Chemother. 2008. 61:1-7. [Abstract] [Full Text] [PDF]

Caroline Foster and Hermione Lyall
HIV and mitochondrial toxicity in children
J. Antimicrob. Chemother. 2008. 61:8-12. [Abstract] [Full Text] [PDF]

Bonaventura Clotet
Once-daily dosing of nevirapine in HAART
J. Antimicrob. Chemother. 2008. 61:13-16. [Abstract] [Full Text] [PDF]

Pierre-Louis Toutain, Alain Bousquet-Melou, and Marilyn Martinez
AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?
J. Antimicrob. Chemother. 2007. 60:1185-1188. [Abstract] [Full Text] [PDF]

Nicola Price and Elizabeth H. Boxall
Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression
J. Antimicrob. Chemother. 2007. 60:1189-1192. [Abstract] [Full Text] [PDF]

Leonard Leibovici and Mical Paul
Aminoglycoside/ß-lactam combinations in clinical practice
J. Antimicrob. Chemother. 2007. 60:911-912. [Abstract] [Full Text] [PDF]

Robert G. Masterton and Michele Caldwell
Improving practice—the Hospital Pharmacy Initiative revisited
J. Antimicrob. Chemother. 2007. 60:709-711. [Abstract] [Full Text] [PDF]

Jonathan Cooke, Peter Davey, Hayley Wickens, Ann Jacklin, Conor Jamieson, Ysobel Gourlay, Kieran Hand, and Sally Wellsteed
Improving practice—working together to improve the use of antimicrobials
J. Antimicrob. Chemother. 2007. 60:712-714. [Abstract] [Full Text] [PDF]

Hanneke K. A. Knaapen and Pilar Barrera
Therapy for Whipple's disease
J. Antimicrob. Chemother. 2007. 60:457-458. [Abstract] [Full Text] [PDF]

Darius Armstrong-James
Invasive Candida species infection: the importance of adequate empirical antifungal therapy
J. Antimicrob. Chemother. 2007. 60:459-460. [Abstract] [Full Text] [PDF]

Nicolai Lohse, Ann-Brit Eg Hansen, Jan Gerstoft, and Niels Obel
Improved survival in HIV-infected persons: consequences and perspectives
J. Antimicrob. Chemother. 2007. 60:461-463. [Abstract] [Full Text] [PDF]

Guangbi Yao
Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
J. Antimicrob. Chemother. 2007. 60:201-205. [Abstract] [Full Text] [PDF]

Carmen Y. Lim and Kris V. Kowdley
Optimal duration of therapy in HBV-related cirrhosis
J. Antimicrob. Chemother. 2007. 60:2-6. [Abstract] [Full Text] [PDF]

Sebastian G. B. Amyes, Fiona M. Walsh, and John S. Bradley
Best in class: a good principle for antibiotic usage to limit resistance development?
J. Antimicrob. Chemother. 2007. 59:825-826. [Abstract] [Full Text] [PDF]

William E. Delaney IV
Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil
J. Antimicrob. Chemother. 2007. 59:827-832. [Abstract] [Full Text] [PDF]

Ian Chopra
The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?
J. Antimicrob. Chemother. 2007. 59:587-590. [Abstract] [Full Text] [PDF]

Andrew Lucas, David Nolan, and Simon Mallal
HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
J. Antimicrob. Chemother. 2007. 59:591-593. [Abstract] [Full Text] [PDF]

F. Goldstein
The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus
J. Antimicrob. Chemother. 2007. 59:1-4. [Abstract] [Full Text] [PDF]

Peter Davey
The potential role of computerized decision support systems to improve empirical antibiotic prescribing
J. Antimicrob. Chemother. 2006. 58:1105-1106. [Abstract] [Full Text] [PDF]

Jane Democratis, Manish Pareek, and Iain Stephenson
Use of neuraminidase inhibitors to combat pandemic influenza
J. Antimicrob. Chemother. 2006. 58:911-915. [Abstract] [Full Text] [PDF]

Y. Horsmans
Interferon-induced depression in chronic hepatitis C
J. Antimicrob. Chemother. 2006. 58:711-713. [Abstract] [Full Text] [PDF]

Vivienne Weston and Gerald Coakley
Guideline for the management of the hot swollen joint in adults with a particular focus on septic arthritis
J. Antimicrob. Chemother. 2006. 58:492-493. [Abstract] [Full Text] [PDF]

D. A. Mitchison
Clinical development of anti-tuberculosis drugs
J. Antimicrob. Chemother. 2006. 58:494-495. [Abstract] [Full Text] [PDF]

Sumita Verma
HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
J. Antimicrob. Chemother. 2006. 58:496-501. [Abstract] [Full Text] [PDF]

Marco Bongiovanni, Maddalena Casana, Camilla Tincati, and Antonella d'Arminio Monforte
Treatment interruptions in HIV-infected subjects
J. Antimicrob. Chemother. 2006. 58:502-505. [Abstract] [Full Text] [PDF]

Mauro Schechter and Suely Hiromi Tuboi
Discordant immunological and virological responses to antiretroviral therapy
J. Antimicrob. Chemother. 2006. 58:506-510. [Abstract] [Full Text] [PDF]

Eugenia Negredo, Anna Bonjoch, and Bonaventura Clotet
Benefits and concerns of simplification strategies in HIV-infected patients
J. Antimicrob. Chemother. 2006. 58:235-242. [Abstract] [Full Text] [PDF]

Mark A. Toleman, Peter M. Bennett, and Timothy R. Walsh
Common regions e.g. orf513 and antibiotic resistance: IS91-like elements evolving complex class 1 integrons
J. Antimicrob. Chemother. 2006. 58:1-6. [Abstract] [Full Text] [PDF]

Diego Rincon, Cristina Ripoll, Maria Vega Catalina, Magdalena Salcedo, and Rafael Banares
Does interferon improve portal hypertension?
J. Antimicrob. Chemother. 2006. 58:7-12. [Abstract] [Full Text] [PDF]

Richard Wise
Antimicrobial resistance: paradox, actions and economics
J. Antimicrob. Chemother. 2006. 57:1024-1025. [Abstract] [Full Text] [PDF]

Matthew J. Ellington and Neil Woodford
Fluoroquinolone resistance and plasmid addiction systems: self-imposed selection pressure?
J. Antimicrob. Chemother. 2006. 57:1026-1029. [Abstract] [Full Text] [PDF]

Melissa K. Osborn and Anna S. F. Lok
Antiviral options for the treatment of chronic hepatitis B
J. Antimicrob. Chemother. 2006. 57:1030-1034. [Abstract] [Full Text] [PDF]

Patricia K. Lee, Tara L. Kieffer, Robert F. Siliciano, and Richard E. Nettles
HIV-1 viral load blips are of limited clinical significance
J. Antimicrob. Chemother. 2006. 57:803-805. [Abstract] [Full Text] [PDF]

Pablo Barreiro and Vincent Soriano
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
J. Antimicrob. Chemother. 2006. 57:806-809. [Abstract] [Full Text] [PDF]

Flavia B. Lillo and Caterina Uberti-Foppa
Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women
J. Antimicrob. Chemother. 2006. 57:810-814. [Abstract] [Full Text] [PDF]

Vincent Soriano, Pablo Barreiro, and Marina Nunez
Management of chronic hepatitis B and C in HIV-coinfected patients
J. Antimicrob. Chemother. 2006. 57:815-818. [Abstract] [Full Text] [PDF]

S. F. Stone, P. Price, and M. A. French
Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease
J. Antimicrob. Chemother. 2006. 57:585-588. [Abstract] [Full Text] [PDF]

R. Scott McClelland and Jared M. Baeten
Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals
J. Antimicrob. Chemother. 2006. 57:163-166. [Abstract] [Full Text] [PDF]

Samuel A. Shelburne, Martin Montes, and Richard J. Hamill
Immune reconstitution inflammatory syndrome: more answers, more questions
J. Antimicrob. Chemother. 2006. 57:167-170. [Abstract] [Full Text] [PDF]

Susan Brown and Sebastian Amyes
OXA ß-lactamases in Acinetobacter: the story so far
J. Antimicrob. Chemother. 2006. 57:1-3. [Abstract] [Full Text] [PDF]

Sophie Grabar, Laurence Weiss, and Dominique Costagliola
HIV infection in older patients in the HAART era
J. Antimicrob. Chemother. 2006. 57:4-7. [Abstract] [Full Text] [PDF]

Robert G. Gish
Treating HCV with ribavirin analogues and ribavirin-like molecules
J. Antimicrob. Chemother. 2006. 57:8-13. [Abstract] [Full Text] [PDF]

Norbert Brau
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy
J. Antimicrob. Chemother. 2005. 56:991-995. [Abstract] [Full Text] [PDF]

S. F. FitzGerald, C. Kelly, and H. Humphreys
Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus
J. Antimicrob. Chemother. 2005. 56:996-999. [Abstract] [Full Text] [PDF]

Ronald B. Turner and J. Owen Hendley
Virucidal hand treatments for prevention of rhinovirus infection
J. Antimicrob. Chemother. 2005. 56:805-807. [Abstract] [Full Text] [PDF]

David M. Livermore
Tigecycline: what is it, and where should it be used?
J. Antimicrob. Chemother. 2005. 56:611-614. [Abstract] [Full Text] [PDF]

S. Mauss and J. K. Rockstroh
HCV/HIV-coinfection—is there a state of the art after APRICOT and RIBAVIC?
J. Antimicrob. Chemother. 2005. 56:615-618. [Abstract] [Full Text] [PDF]

Tamiko Hisanaga, Daryl J. Hoban, and George G. Zhanel
Mechanisms of resistance to telithromycin in Streptococcus pneumoniae
J. Antimicrob. Chemother. 2005. 56:447-450. [Abstract] [Full Text] [PDF]

Pentti Huovinen
Mathematical model—tell us the future!
J. Antimicrob. Chemother. 2005. 56:257-258. [Abstract] [Full Text] [PDF]

Neil Woodford and Arnfinn Sundsfjord
Molecular detection of antibiotic resistance: when and where?
J. Antimicrob. Chemother. 2005. 56:259-261. [Abstract] [Full Text] [PDF]

Catherine Yates and Sebastian Amyes
Extended-spectrum ß-lactamases in non-typhoidal Salmonella spp. isolated in the UK are now a reality: why the late arrival?
J. Antimicrob. Chemother. 2005. 56:262-264. [Abstract] [Full Text] [PDF]

J. Gerardo Garcia-Lerma
Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons
J. Antimicrob. Chemother. 2005. 56:265-269. [Abstract] [Full Text] [PDF]

Kurt Vermeire and Dominique Schols
Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs
J. Antimicrob. Chemother. 2005. 56:270-272. [Abstract] [Full Text] [PDF]

Susan S. Kaplan and Charles B. Hicks
Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection
J. Antimicrob. Chemother. 2005. 56:273-276. [Abstract] [Full Text] [PDF]

Edward Gershburg and Joseph S. Pagano
Epstein–Barr virus infections: prospects for treatment
J. Antimicrob. Chemother. 2005. 56:277-281. [Abstract] [Full Text] [PDF]

Alan Winston and Marta Boffito
The management of HIV-1 protease inhibitor pharmacokinetic interactions
J. Antimicrob. Chemother. 2005. 56:1-5. [Abstract] [Full Text] [PDF]

Ana Milinkovic and Esteban Martinez
Current perspectives on HIV-associated lipodystrophy syndrome
J. Antimicrob. Chemother. 2005. 56:6-9. [Abstract] [Full Text] [PDF]

Robert W. Shafer and Jonathan M. Schapiro
Drug resistance and antiretroviral drug development
J. Antimicrob. Chemother. 2005. 55:817-820. [Abstract] [Full Text] [PDF]

Franco Maggiolo, Diego Ripamonti, and Fredy Suter
Switch strategies in patients on effective HAART
J. Antimicrob. Chemother. 2005. 55:821-823. [Abstract] [Full Text] [PDF]

Angel Luis Ballesteros, Daniel Fuster, Ramon Planas, Bonaventura Clotet, and Cristina Tural
Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients
J. Antimicrob. Chemother. 2005. 55:824-827. [Abstract] [Full Text] [PDF]

Ramazan Idilman
Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy
J. Antimicrob. Chemother. 2005. 55:828-831. [Abstract] [Full Text] [PDF]

Johan W. Mouton, Michael N. Dudley, Otto Cars, Hartmut Derendorf, and George L. Drusano
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
J. Antimicrob. Chemother. 2005. 55:601-607. [Abstract] [Full Text] [PDF]

Fabien Zoulim
Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models
J. Antimicrob. Chemother. 2005. 55:608-611. [Abstract] [Full Text] [PDF]

Allison Martin and Patrick W. G. Mallon
Therapeutic approaches to combating lipoatrophy: do they work?
J. Antimicrob. Chemother. 2005. 55:612-615. [Abstract] [Full Text] [PDF]

Giulia Marchetti, Fabio Franzetti, and Andrea Gori
Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
J. Antimicrob. Chemother. 2005. 55:401-409. [Abstract] [Full Text] [PDF]

Ann Noe, Jean Plum, and Chris Verhofstede
The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance
J. Antimicrob. Chemother. 2005. 55:410-412. [Abstract] [Full Text] [PDF]

Gregory M. Lucas
Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven
J. Antimicrob. Chemother. 2005. 55:413-416. [Abstract] [Full Text] [PDF]

Juan A. Pineda and Juan Macias
Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy
J. Antimicrob. Chemother. 2005. 55:417-419. [Abstract] [Full Text] [PDF]

Marla J. Keller, Ana Tuyama, Maria Josefina Carlucci, and Betsy C. Herold
Topical microbicides for the prevention of genital herpes infection
J. Antimicrob. Chemother. 2005. 55:420-423. [Abstract] [Full Text] [PDF]

Judith N. Steenbergen, Jeff Alder, Grace M. Thorne, and Francis P. Tally
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
J. Antimicrob. Chemother. 2005. 55:283-288. [Abstract] [Full Text] [PDF]

Christopher Cianci, Nicholas Meanwell, and Mark Krystal
Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor
J. Antimicrob. Chemother. 2005. 55:289-292. [Abstract] [Full Text] [PDF]

Jan Balzarini, Miguel Stevens, Erik De Clercq, Dominique Schols, and Christophe Pannecouque
Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action
J. Antimicrob. Chemother. 2005. 55:135-138. [Abstract] [Full Text] [PDF]

Norio Akuta and Hiromitsu Kumada
Influence of hepatitis B virus genotypes on the response to antiviral therapies
J. Antimicrob. Chemother. 2005. 55:139-142. [Abstract] [Full Text] [PDF]

Robert G. Masterton
Antibiotic cycling: more than it might seem?
J. Antimicrob. Chemother. 2005. 55:1-5. [Abstract] [Full Text] [PDF]

Chien-Ching Hung and Shan-Chwen Chang
Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections
J. Antimicrob. Chemother. 2004. 54:849-853. [Abstract] [Full Text] [PDF]

Daniel K. Benjamin Jr, Steven Hirschfeld, Coleen K. Cunningham, and Ross E. McKinney Jr
Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials
J. Antimicrob. Chemother. 2004. 54:701-703. [Abstract] [Full Text] [PDF]

Javier Rojo and Rafael Delgado
Glycodendritic structures: promising new antiviral drugs
J. Antimicrob. Chemother. 2004. 54:579-581. [Abstract] [Full Text] [PDF]

Kathryn L. Springer and Adriana Weinberg
Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity
J. Antimicrob. Chemother. 2004. 54:582-586. [Abstract] [Full Text] [PDF]

T. M. A. Weller and C. E. Jamieson
The expanding role of the antibiotic pharmacist
J. Antimicrob. Chemother. 2004. 54:295-298. [Abstract] [Full Text] [PDF]

Philip J. Budge and Barney S. Graham
Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses
J. Antimicrob. Chemother. 2004. 54:299-302. [Abstract] [Full Text] [PDF]

Heiner C. Bucher, James Young, and Manuel Battegay
Protease inhibitor-sparing simplified maintenance therapy: a need for perspective
J. Antimicrob. Chemother. 2004. 54:303-305. [Abstract] [Full Text] [PDF]

Mike Bray and Chad J. Roy
Antiviral prophylaxis of smallpox
J. Antimicrob. Chemother. 2004. 54:1-5. [Abstract] [Full Text] [PDF]

Janet D. Siliciano and Robert F. Siliciano
A long-term latent reservoir for HIV-1: discovery and clinical implications
J. Antimicrob. Chemother. 2004. 54:6-9. [Abstract] [Full Text] [PDF]

Amanda Mocroft and Jens D. Lundgren
Starting highly active antiretroviral therapy: why, when and response to HAART
J. Antimicrob. Chemother. 2004. 54:10-13. [Abstract] [Full Text] [PDF]

Robert T. Sarisky
Non-nucleoside inhibitors of the HCV polymerase
J. Antimicrob. Chemother. 2004. 54:14-16. [Abstract] [Full Text] [PDF]

Norbert Hubert Gruener, Maria-Christina Jung, and Carl Albrecht Schirren
Recurrent hepatitis C virus infection after liver transplantation: natural course, therapeutic approach and possible mechanisms of viral control
J. Antimicrob. Chemother. 2004. 54:17-20. [Abstract] [Full Text] [PDF]

Golo Ahlenstiel, Rainer P. Woitas, Jurgen Rockstroh, and Ulrich Spengler
CC-chemokine receptor 5 (CCR5) in hepatitis C—at the crossroads of the antiviral immune response?
J. Antimicrob. Chemother. 2004. 53:895-898. [Abstract] [Full Text] [PDF]

Conan MacDougall and B. Joseph Guglielmo
Pharmacokinetics of valaciclovir
J. Antimicrob. Chemother. 2004. 53:899-901. [Abstract] [Full Text] [PDF]

Lance R. Peterson and Axel Dalhoff
Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?
J. Antimicrob. Chemother. 2004. 53:902-905. [Abstract] [Full Text] [PDF]

A. D. Russell
Whither triclosan?
J. Antimicrob. Chemother. 2004. 53:693-695. [Abstract] [Full Text] [PDF]

David R. Bangsberg, Andrew R. Moss, and Steven G. Deeks
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
J. Antimicrob. Chemother. 2004. 53:696-699. [Abstract] [Full Text] [PDF]

J. K. Rockstroh and S. Mauss
Clinical perspective of fusion inhibitors for treatment of HIV
J. Antimicrob. Chemother. 2004. 53:700-702. [Abstract] [Full Text] [PDF]

Spotswood L. Spruance and Joanne Hill
Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials
J. Antimicrob. Chemother. 2004. 53:703-707. [Abstract] [Full Text] [PDF]

Douglas D. Richman
Benefits and limitations of testing for resistance to HIV drugs
J. Antimicrob. Chemother. 2004. 53:555-557. [Abstract] [Full Text] [PDF]

Yazdan Yazdanpanah
Costs associated with combination antiretroviral therapy in HIV-infected patients
J. Antimicrob. Chemother. 2004. 53:558-561. [Abstract] [Full Text] [PDF]

Victor E. Buckwold
Implications of finding synergic in vitro drug–drug interactions between interferon-{alpha} and ribavirin for the treatment of hepatitis C virus
J. Antimicrob. Chemother. 2004. 53:413-414. [Abstract] [Full Text] [PDF]

Emilio Fumero, Felipe Garcia, and J. M. Gatell
Immunosuppressive drugs as an adjuvant to HIV treatment
J. Antimicrob. Chemother. 2004. 53:415-417. [Abstract] [Full Text] [PDF]

Beverley C. Millar and John E. Moore
Antibiotic prophylaxis, body piercing and infective endocarditis
J. Antimicrob. Chemother. 2004. 53:123-126. [Abstract] [Full Text] [PDF]

Louis Bernard, Pierre Hoffmeyer, Mathieu Assal, Pierre Vaudaux, Jacques Schrenzel, and Daniel Lew
Trends in the treatment of orthopaedic prosthetic infections
J. Antimicrob. Chemother. 2004. 53:127-129. [Abstract] [Full Text] [PDF]

Ben de Pauw
Preventative use of antifungal drugs in patients treated for cancer
J. Antimicrob. Chemother. 2004. 53:130-132. [Abstract] [Full Text] [PDF]

John Oxford, Shobana Balasingam, and Rob Lambkin
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
J. Antimicrob. Chemother. 2004. 53:133-136. [Abstract] [Full Text] [PDF]

Hans-Ulrich Bernard
Established and potential strategies against papillomavirus infections
J. Antimicrob. Chemother. 2004. 53:137-139. [Abstract] [Full Text] [PDF]

Elisabeta Vergu, Alain Mallet, and Jean-Louis Golmard
Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection
J. Antimicrob. Chemother. 2004. 53:140-143. [Abstract] [Full Text] [PDF]

Justin Stebbing, Philip Savage, Steve Patterson, and Brian Gazzard
All for CD91 and CD91 for all
J. Antimicrob. Chemother. 2004. 53:1-3. [Abstract] [Full Text] [PDF]

Robert K. Zeldin and Richard A. Petruschke
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
J. Antimicrob. Chemother. 2004. 53:4-9. [Abstract] [Full Text] [PDF]

Leonardo Calza, Roberto Manfredi, and Francesco Chiodo
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients
J. Antimicrob. Chemother. 2004. 53:10-14. [Abstract] [Full Text] [PDF]

Peter Ferenci
Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
J. Antimicrob. Chemother. 2004. 53:15-18. [Abstract] [Full Text] [PDF]

Keisuke Hino and Kiwamu Okita
Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C
J. Antimicrob. Chemother. 2004. 53:19-22. [Abstract] [Full Text] [PDF]

Fang Fang and Mang Yu
Viral receptor blockage by multivalent recombinant antibody fusion proteins: inhibiting human rhinovirus (HRV) infection with CFY196
J. Antimicrob. Chemother. 2004. 53:23-25. [Abstract] [Full Text] [PDF]

John Turnidge
Antibiotic use in animals—prejudices, perceptions and realities
J. Antimicrob. Chemother. 2004. 53:26-27. [Abstract] [Full Text] [PDF]

Shirit Einav and Jeffrey S. Glenn
Prenylation inhibitors: a novel class of antiviral agents
J. Antimicrob. Chemother. 2003. 52:883-886. [Abstract] [Full Text] [PDF]

Melissa M. Herbst and Richard B. Pyles
Immunostimulatory CpG treatment for genital HSV-2 infections
J. Antimicrob. Chemother. 2003. 52:887-889. [Full Text] [PDF]

John P. Moore and Robin J. Shattock
Preventing HIV-1 sexual transmission—not sexy enough science, or no benefit to the bottom line?
J. Antimicrob. Chemother. 2003. 52:890-892. [Full Text] [PDF]

Johannes A. Bogaards and Jaap Goudsmit
Meeting the immense need for HAART in resource-poor settings
J. Antimicrob. Chemother. 2003. 52:743-746. [Full Text] [PDF]

Anthony Kebba
Antiretroviral therapy in sub-Saharan Africa: myth or reality?
J. Antimicrob. Chemother. 2003. 52:747-749. [Full Text] [PDF]

Pramod M. Shah and Robin D. Isaacs
Ertapenem, the first of a new group of carbapenems
J. Antimicrob. Chemother. 2003. 52:538-542. [Full Text] [PDF]

Jim Zhen Wu, Chin-chung Lin, and Zhi Hong
Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design
J. Antimicrob. Chemother. 2003. 52:543-546. [Full Text] [PDF]

Nancy A. Jewell, Renxiang Chen, Raquel Raices, and Louis M. Mansky
Nucleoside reverse transcriptase inhibitors and HIV mutagenesis
J. Antimicrob. Chemother. 2003. 52:547-550. [Full Text] [PDF]

A. Fraternale, A. Casabianca, L. Rossi, L. Chiarantini, G. F. Schiavano, A. T. Palamara, E. Garaci, and M. Magnani
Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections
J. Antimicrob. Chemother. 2003. 52:551-554. [Full Text] [PDF]

Denise Paulsen, Robert Elston, Wendy Snowden, Margaret Tisdale, and Lisa Ross
Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects
J. Antimicrob. Chemother. 2003. 52:319-323. [Full Text] [PDF]

Gunnar Kahlmeter, Derek F. J. Brown, Fred W. Goldstein, Alasdair P. MacGowan, Johan W. Mouton, Anders Osterlund, Arne Rodloff, Martin Steinbakk, Pavla Urbaskova, and Alkiviadis Vatopoulos
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
J. Antimicrob. Chemother. 2003. 52:145-148. [Full Text] [PDF]

Shiou-Hwei Yeh, Ding-Shinn Chen, and Pei-Jer Chen
A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis
J. Antimicrob. Chemother. 2003. 52:149-151. [Full Text] [PDF]

Michelle Swanson-Mungerson, Masato Ikeda, Lori Lev, Richard Longnecker, and Toni Portis
Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases
J. Antimicrob. Chemother. 2003. 52:152-154. [Full Text] [PDF]

Rafael de la Rosa and Manuel Leal
Thymic involvement in recovery of immunity among HIV-infected adults on highly active antiretroviral therapy
J. Antimicrob. Chemother. 2003. 52:155-158. [Full Text] [PDF]

Nancy D. Hanson
AmpC ß-lactamases: what do we need to know for the future?
J. Antimicrob. Chemother. 2003. 52:2-4. [Full Text] [PDF]

K. Kummerer
Significance of antibiotics in the environment
J. Antimicrob. Chemother. 2003. 52:5-7. [Full Text] [PDF]

Noboru Uchide and Kunio Ohyama
Antiviral function of pyrrolidine dithiocarbamate against influenza virus: the inhibition of viral gene replication and transcription
J. Antimicrob. Chemother. 2003. 52:8-10. [Full Text] [PDF]

Heather J. Smith, Kimberly A. Nichol, Daryl J. Hoban, and George G. Zhanel
Stretching the mutant prevention concentration (MPC) beyond its limits
J. Antimicrob. Chemother. 2003. 51:1323-1325. [Full Text] [PDF]

Beatrice Macchi, Emanuela Balestrieri, and Antonio Mastino
Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro
J. Antimicrob. Chemother. 2003. 51:1327-1330. [Full Text] [PDF]

F. Van Bambeke, Y. Glupczynski, P. Plesiat, J. C. Pechere, and P. M. Tulkens
Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy
J. Antimicrob. Chemother. 2003. 51:1055-1065. [Full Text] [PDF]

F. Van Bambeke, J.-M. Michot, and P. M. Tulkens
Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics
J. Antimicrob. Chemother. 2003. 51:1067-1077. [Full Text] [PDF]

Erik De Clercq
New inhibitors of human cytomegalovirus (HCMV) on the horizon
J. Antimicrob. Chemother. 2003. 51:1079-1083. [Full Text] [PDF]

Naohiro Kamiya
The mechanisms of action of antivirals against hepatitis B virus infection
J. Antimicrob. Chemother. 2003. 51:1085-1089. [Full Text] [PDF]

Catherine L. Cherry and Steven L. Wesselingh
Nucleoside analogues and HIV: the combined cost to mitochondria
J. Antimicrob. Chemother. 2003. 51:1091-1093. [Full Text] [PDF]

Justin Stebbing, Simon Portsmouth, and Brian Gazzard
How does HAART lead to the resolution of Kaposi’s sarcoma?
J. Antimicrob. Chemother. 2003. 51:1095-1098. [Full Text] [PDF]

Marla J. Keller, Mary E. Klotman, and Betsy C. Herold
Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus
J. Antimicrob. Chemother. 2003. 51:1099-1102. [Full Text] [PDF]

Dilip Nathwani
From evidence-based guideline methodology to quality of care standards
J. Antimicrob. Chemother. 2003. 51:1103-1107. [Full Text] [PDF]

Scott D. Mills
The role of genomics in antimicrobial discovery
J. Antimicrob. Chemother. 2003. 51:749-752. [Full Text] [PDF]

Glen A. Coburn and Bryan R. Cullen
siRNAs: a new wave of RNA-based therapeutics
J. Antimicrob. Chemother. 2003. 51:753-756. [Full Text] [PDF]

Gabriela Stiegler and Hermann Katinger
Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection
J. Antimicrob. Chemother. 2003. 51:757-759. [Full Text] [PDF]

Man-Fung Yuen and Ching-Lung Lai
Current and future antiviral agents for chronic hepatitis B
J. Antimicrob. Chemother. 2003. 51:481-485. [Full Text] [PDF]

Samuel S. Lee and Ayman A. Abdo
Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?
J. Antimicrob. Chemother. 2003. 51:487-491. [Full Text] [PDF]

Patrick G. Hoggard and Andrew Owen
The mechanisms that control intracellular penetration of the HIV protease inhibitors
J. Antimicrob. Chemother. 2003. 51:493-496. [Full Text] [PDF]

Paolo Monini, Cecilia Sgadari, Giovanni Barillari, and Barbara Ensoli
HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity
J. Antimicrob. Chemother. 2003. 51:207-211. [Full Text] [PDF]

Graeme Moyle
Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART
J. Antimicrob. Chemother. 2003. 51:213-217. [Full Text] [PDF]

Damian J. McColl and Michael D. Miller
The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1
J. Antimicrob. Chemother. 2003. 51:219-223. [Full Text] [PDF]

Federico Pulido and Jose R. Arribas
Treatment of advanced HIV infection
J. Antimicrob. Chemother. 2003. 51:225-227. [Full Text] [PDF]

Christoph G. Lange and Michael M. Lederman
Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection
J. Antimicrob. Chemother. 2003. 51:1-4. [Full Text] [PDF]

George M. Bahr
Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide
J. Antimicrob. Chemother. 2003. 51:5-8. [Full Text] [PDF]

M. A. Webber and L. J. V. Piddock
The importance of efflux pumps in bacterial antibiotic resistance
J. Antimicrob. Chemother. 2003. 51:9-11. [Full Text] [PDF]

J. Gerardo Garcia-Lerma and Walid Heneine
Rapid biochemical assays for phenotypic drug resistance testing of HIV-1
J. Antimicrob. Chemother. 2002. 50:771-774. [Full Text] [PDF]

Gunnar Kahlmeter and Derek F. J. Brown
Resistance surveillance studies—comparability of results and quality assurance of methods
J. Antimicrob. Chemother. 2002. 50:775-777. [Full Text] [PDF]

Alan P. Johnson and Neil Woodford
Glycopeptide-resistant Staphylococcus aureus
J. Antimicrob. Chemother. 2002. 50:621-623. [Full Text] [PDF]

A. Sullivan and C. E. Nord
Probiotics in human infections
J. Antimicrob. Chemother. 2002. 50:625-627. [Full Text] [PDF]

Tuofu Zhu
HIV-1 in peripheral blood monocytes: an underrated viral source
J. Antimicrob. Chemother. 2002. 50:309-311. [Full Text] [PDF]

Pietro E. Varaldo
Antimicrobial resistance and susceptibility testing: an evergreen topic
J. Antimicrob. Chemother. 2002. 50:1-4. [Full Text] [PDF]

David W. Denning
Echinocandins: a new class of antifungal
J. Antimicrob. Chemother. 2002. 49:889-891. [Full Text] [PDF]

Heather J. Smith, Kimberly A. Nichol, Daryl J. Hoban, and George G. Zhanel
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
J. Antimicrob. Chemother. 2002. 49:893-895. [Full Text] [PDF]

H. Lode and M. Allewelt
Role of newer fluoroquinolones in lower respiratory tract infections
J. Antimicrob. Chemother. 2002. 49:709-712. [Full Text] [PDF]

Richard Wise
Antimicrobial resistance: priorities for action
J. Antimicrob. Chemother. 2002. 49:585-586. [Full Text] [PDF]

Erwin M. Brown
Guidelines for antibiotic usage in hospitals
J. Antimicrob. Chemother. 2002. 49:587-592. [Full Text] [PDF]

Ethan Rubinstein and John Camm
Cardiotoxicity of fluoroquinolones
J. Antimicrob. Chemother. 2002. 49:593-596. [Full Text] [PDF]

A. D. Russell
Mechanisms of antimicrobial action of antiseptics and disinfectants: an increasingly important area of investigation
J. Antimicrob. Chemother. 2002. 49:597-599. [Full Text] [PDF]

William Bishai
The in vivo–in vitro paradox in pneumococcal respiratory tract infections
J. Antimicrob. Chemother. 2002. 49:433-436. [Full Text] [PDF]

Helen Giamarellou
Prescribing guidelines for severe Pseudomonas infections
J. Antimicrob. Chemother. 2002. 49:229-233. [Full Text] [PDF]

Niels Hoiby
New antimicrobials in the management of cystic fibrosis
J. Antimicrob. Chemother. 2002. 49:235-238. [Full Text] [PDF]

Georg Maschmeyer
New antifungal agents—treatment standards are beginning to grow old
J. Antimicrob. Chemother. 2002. 49:239-241. [Full Text] [PDF]

Deirdre Lewis
Antimicrobial resistance surveillance: methods will depend on objectives
J. Antimicrob. Chemother. 2002. 49:3-5. [Full Text] [PDF]

A. K. Morris and R. G. Masterton
Antibiotic resistance surveillance: action for international studies
J. Antimicrob. Chemother. 2002. 49:7-10. [Full Text] [PDF]

A. P. Fraise
Biocide abuse and antimicrobial resistance—a cause for concern?
J. Antimicrob. Chemother. 2002. 49:11-12. [Full Text] [PDF]

B. Chattopadhyay
Newborns and gentamicin—how much and how often?
J. Antimicrob. Chemother. 2002. 49:13-16. [Full Text] [PDF]

Caroline A. Sabin and Andrew N. Phillips
Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies
J. Antimicrob. Chemother. 2001. 47:371-375. [Full Text] [PDF]

David M. Livermore
Of Pseudomonas, porins, pumps and carbapenems
J. Antimicrob. Chemother. 2001. 47:247-250. [Full Text] [PDF]

Marc D. Cubbon and Robert G. Masterton
New quinolones—a fresh answer to the pneumococcus
J. Antimicrob. Chemother. 2000. 46:869-872. [Full Text] [PDF]

Elizabeth H. Price, John de Louvois, and M. Rella Workman
Antibiotics for Salmonella meningitis in children
J. Antimicrob. Chemother. 2000. 46:653-655. [Full Text] [PDF]

Francis P. Tally and Michael F. DeBruin
Development of daptomycin for Gram-positive infections
J. Antimicrob. Chemother. 2000. 46:523-526. [Full Text] [PDF]

David M. Livermore
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
J. Antimicrob. Chemother. 2000. 46:347-350. [Full Text] [PDF]

Kurt G. Naber and Wolfgang Weidner
Chronic prostatitis—an infectious disease?
J. Antimicrob. Chemother. 2000. 46:157-161. [Full Text] [PDF]

Heike Brotz and Hans-Georg Sahl
New insights into the mechanism of action of lantibiotics—diverse biological effects by binding to the same molecular target
J. Antimicrob. Chemother. 2000. 46:1-6. [Full Text] [PDF]

E. John Threlfall
Epidemic Salmonella typhimurium DT 104—a truly international multiresistant clone
J. Antimicrob. Chemother. 2000. 46:7-10. [Full Text] [PDF]

Kenneth S. Thomson
Minimizing quinolone resistance: are the new agents more or less likely to cause resistance?
J. Antimicrob. Chemother. 2000. 45:719-723. [Full Text] [PDF]

S. Esposito
Outpatient parenteral treatment of bacterial infections: the Italian model as an international trend?
J. Antimicrob. Chemother. 2000. 45:724-727. [Full Text] [PDF]

Peter Ball
Quinolone-induced QT interval prolongation: a not-so-unexpected class effect
J. Antimicrob. Chemother. 2000. 45:557-559. [Full Text] [PDF]

Susan M. Drake
NNRTIs—a new class of drugs for HIV
J. Antimicrob. Chemother. 2000. 45:417-420. [Full Text] [PDF]

Issam Raad
Management of intravascular catheter-related infections
J. Antimicrob. Chemother. 2000. 45:267-270. [Full Text] [PDF]

M. Youle
Is interruption of HIV therapy always harmful?
J. Antimicrob. Chemother. 2000. 45:137-138. [Full Text] [PDF]

Jeffrey R. Edwards and Michael J. Betts
Carbapenems: the pinnacle of the ß-lactam antibiotics or room for improvement?
J. Antimicrob. Chemother. 2000. 45:1-4. [Full Text] [PDF]

S. Ragnar Norrby
Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis
J. Antimicrob. Chemother. 2000. 45:5-7. [Full Text] [PDF]

Ian Phillips
The use of bacitracin as a growth promoter in animals produces no risk to human health
J. Antimicrob. Chemother. 1999. 44:725-728. [Full Text] [PDF]

Kevin G. Kerr
The prophylaxis of bacterial infections in neutropenic patients
J. Antimicrob. Chemother. 1999. 44:587-591. [Full Text] [PDF]

Joanne M. Legg and Adrian J. Bint
Will pneumococci put quinolones in their place?
J. Antimicrob. Chemother. 1999. 44:425-427. [Full Text] [PDF]

Fred W. Goldstein
Penicillin-resistant Streptococcus pneumoniae: selection by both ß-lactam and non-ß-lactam antibiotics
J. Antimicrob. Chemother. 1999. 44:141-144. [Full Text] [PDF]

P. J. Cook
Antimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma
J. Antimicrob. Chemother. 1999. 44:145-148. [Full Text] [PDF]

Guy W. Amsden
Pneumococcal macrolide resistance—myth or reality?
J. Antimicrob. Chemother. 1999. 44:1-6. [Full Text] [PDF]

Iain Stephenson and Karl G. Nicholson
Chemotherapeutic control of influenza
J. Antimicrob. Chemother. 1999. 44:6-10. [Full Text] [PDF]

Martin Dedicoat and Pradhib Venkatesan
The treatment of Legionnaires' disease
J. Antimicrob. Chemother. 1999. 43:747-752. [Full Text] [PDF]

Tom S. J. Elliott
Role of antimicrobial central venous catheters for the prevention of associated infections
J. Antimicrob. Chemother. 1999. 43:441-446. [Full Text] [PDF]

Omrum Uzun and Elias J. Anaissie
Outpatient therapy for febrile neutropenia: who, when and how?
J. Antimicrob. Chemother. 1999. 43:317-320. [Full Text] [PDF]

Lee Ann Thal and Marcus J. Zervos
Occurrence and epidemiology of resistance to virginiamycin and streptogramins
J. Antimicrob. Chemother. 1999. 43:171-176. [Full Text] [PDF]

Peter M. Bennett
Integrons and gene cassettes: a genetic construction kit for bacteria
J. Antimicrob. Chemother. 1999. 43:1-4. [Full Text] [PDF]

JL Martinez, A Alonso, JM Gomez-Gomez, and F Baquero
Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
J. Antimicrob. Chemother. 1998. 42:683-688. [PDF]

RG Finch, DI Pritchard, BW Bycroft, P Williams, and GS Stewart
Quorum sensing: a novel target for anti-infective therapy
J. Antimicrob. Chemother. 1998. 42:569-571. [PDF]

SG Amyes and RS Miles
Extended-spectrum beta-lactamases: the role of inhibitors in therapy
J. Antimicrob. Chemother. 1998. 42:415-417. [PDF]

AP Fraise
Guidelines for the control of methicillin-resistant Staphylococcus aureus
J. Antimicrob. Chemother. 1998. 42:287-289. [PDF]

RG Finch
Antibiotic resistance
J. Antimicrob. Chemother. 1998. 42:125-128. [PDF]

AF Goddard
Getting to the route of Helicobacter pylori treatment
J. Antimicrob. Chemother. 1998. 42:1-3. [PDF]

H Labischinski, K Ehlert, and B Berger-Bachi
The targeting of factors necessary for expression of methicillin resistance in staphylococci
J. Antimicrob. Chemother. 1998. 41:581-584. [PDF]

DJ Leaper
Use of antibiotic prophylaxis in clean non-implant wounds
J. Antimicrob. Chemother. 1998. 41:501-504. [PDF]

FR Falkiner
The consequences of antibiotic use in horticulture
J. Antimicrob. Chemother. 1998. 41:429-431. [PDF]

JP Burnie and RC Matthews
The renaissance of antibody therapy
J. Antimicrob. Chemother. 1998. 41:319-322. [PDF]

P Venkatesan
Albendazole
J. Antimicrob. Chemother. 1998. 41:145-147. [PDF]

RD Walker and C Thornsberry
Decrease in antibiotic susceptibility or increase in resistance?
J. Antimicrob. Chemother. 1998. 41:1-4. [PDF]

M Whitby
Drug resistant Plasmodium vivax malaria
J. Antimicrob. Chemother. 1997. 40:749-752. [PDF]

DW Denning
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
J. Antimicrob. Chemother. 1997. 40:611-614. [PDF]

EM Brown
Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia
J. Antimicrob. Chemother. 1997. 40:463-468. [PDF]

R Booy and JS Kroll
Is Haemophilus influenzae finished?
J. Antimicrob. Chemother. 1997. 40:149-153. [PDF]

MH Nicolas-Chanoine
Inhibitor-resistant beta-lactamases
J. Antimicrob. Chemother. 1997. 40:1-3. [PDF]

DM Livermore
Acquired carbapenemases
J. Antimicrob. Chemother. 1997. 39:673-676. [PDF]

SA Locarnini and JE Newbold
Chronic hepatitis B: the therapeutic challenge
J. Antimicrob. Chemother. 1997. 39:559-562. [PDF]

D Nathwani, G Tillotson, and P Davey
Sequential antimicrobial therapy--the role of quinolones
J. Antimicrob. Chemother. 1997. 39:441-446. [PDF]

HM Taylor and JB Bingham
Antibiotic prophylaxis for transrectal prostate biopsy
J. Antimicrob. Chemother. 1997. 39:115-117. [PDF]

K Bush and G Jacoby
Nomenclature of TEM beta-lactamases
J. Antimicrob. Chemother. 1997. 39:1-3. [PDF]

GRAEME J. MOYLE and SIMON E. BARTON
HIV-proteinase inhibitors in the management of HIV-infection
J. Antimicrob. Chemother. 1996. 38:921-925. [PDF]

ADAM P FRAISE
The treatment and control of vancomycin-resistant enterococci
J. Antimicrob. Chemother. 1996. 38:753-756. [PDF]

CHRISTOPHER P. CONLON
Outpatient intravenous antibiotic therapy
J. Antimicrob. Chemother. 1996. 38:557-559. [PDF]

HILARY HUMPHREYS and THOMAS WALLEY
Patient packs and the prescribing of antimicrobial agents
J. Antimicrob. Chemother. 1996. 38:329-331. [PDF]

S. AKHTAR and J. J. ROSSI
Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
J. Antimicrob. Chemother. 1996. 38:159-165. [PDF]

LAURA J. V. PIDDOCK
Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy?
J. Antimicrob. Chemother. 1996. 38:1-3. [PDF]

SARAH GANDER
Bacterial biofllms: resistance to antimicrobial agents: J Anlimicrob Chemother 1996; 37: 1047–1050
J. Antimicrob. Chemother. 1996. 37:1047-1050. [PDF]

ANDREW F. GODDARD and ROBERT P. H. LOGAN
Antimicrobial resistance and Helicobacter pylori
J. Antimicrob. Chemother. 1996. 37:639-643. [PDF]

JANE H. LANGFORD and SHALOM I. BENRIMOJ
Clinical rationale for topical antimicrobial preparations
J. Antimicrob. Chemother. 1996. 37:399-402. [PDF]

ROBERT WILSON, GLENN TILLOTSON, and PETER BALL
Clinical studies in chronic bronchitis: a need for better definition and classification of severity
J. Antimicrob. Chemother. 1996. 37:205-208. [PDF]

ALASDAIR MACGOWAN
Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy?: J Antimicrob Chemother 1996; 37: 1–5
J. Antimicrob. Chemother. 1996. 37:1-5. [PDF]

P. D. O. DAVIES
Multiple drug resistant tuberculosis: centralized mycobacterial reference using molecular techniques can help: J Antimicrob Chemother 1996; 37: 5–6
J. Antimicrob. Chemother. 1996. 37:5-6. [PDF]

A. M. SHIBL, J.-C. PECHERE, and M. A. RAMADAN
Postantibiotic effect and host-bacteria interactions
J. Antimicrob. Chemother. 1995. 36:885-887. [PDF]

P. PERITI
Evolution of the bacterial dihydrofolate reductase inhibitors
J. Antimicrob. Chemother. 1995. 36:887-890. [PDF]

ELIZABETH M. JOHNSON and DAVID W. WARNOCK
Azole drug resistance in yeasts
J. Antimicrob. Chemother. 1995. 36:751-755. [PDF]

D. GERAINT JAMES
Treatment options for chronic hepatitis C infection
J. Antimicrob. Chemother. 1995. 36:591-593. [PDF]

RON DAGAN
Why should paediatric patients with serious infections be hospitalized?
J. Antimicrob. Chemother. 1995. 36:451-452. [PDF]

N. J. SAUNDERS
Vancomycin administration and monitoring reappraisal
J. Antimicrob. Chemother. 1995. 36:279-282. [PDF]

A.P.R. WILSON
Antibiotic prophylaxis and infection control measures in minimally invasive surgery
J. Antimicrob. Chemother. 1995. 36:1-5. [PDF]

A. P. R. WILSON
Treatment of infection caused by toxigenic and Bon-toxigenic strains of Corynebacterium diphtheriae
J. Antimicrob. Chemother. 1995. 35:717-720. [PDF]

GEORGE R. BAILIE and GEORGE EISELE
Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis
J. Antimicrob. Chemother. 1995. 35:563-567. [PDF]

F. T. TALLY, G. A. ELLESTAD, and R. T. TESTA
Glycylcyclines: a new generation of tetracyclines
J. Antimicrob. Chemother. 1995. 35:449-452. [PDF]

A. W. SMITH
Stationary phase induction in Escherichia coli—new targets for antimicrobial therapy?
J. Antimicrob. Chemother. 1995. 35:359-361. [PDF]

M. A. VIVIANI
Flucytosine—what is its future?
J. Antimicrob. Chemother. 1995. 35:241-244. [PDF]

D. LIVINGSTONE, M. J. GILL, and R. WISE
Mechanisms of resistance to the carbapenems
J. Antimicrob. Chemother. 1995. 35:1-5. [PDF]

DAVIS S. REEVES
Fosfomycin trometamol
J. Antimicrob. Chemother. 1994. 34:853-858. [PDF]

B. RUF and J. SANDFORT
Human microsporidiosis: J Antimicrob Chemother 1994, 34: 609–611
J. Antimicrob. Chemother. 1994. 34:609-611. [PDF]

KEITH POOLE
Bacterial multidrug resistance—emphasis on efflux mechanisms and Pseudomonas aeruginosa
J. Antimicrob. Chemother. 1994. 34:453-456. [PDF]

PHILIPPA EASTERBROOK and MARTIN J. WOOD
Leading article
J. Antimicrob. Chemother. 1994. 34:307-311. [PDF]

K. P. KLUGMAN
Management of antibiotic-resistant pneumococcal infections
J. Antimicrob. Chemother. 1994. 34:191-193. [PDF]

Drug intolerance in HIV disease
J. Antimicrob. Chemother. 1994. 34:1-5. [PDF]

LINDA C. NEW and RICHARD E. HOLLIMAN
Toxoplasmosis and human immunodeficiency virus (HIV) disease
J. Antimicrob. Chemother. 1994. 33:1079-1082. [PDF]

N. CLUMECK
Antimicrobial prophylaxis in HIV-infected adults
J. Antimicrob. Chemother. 1994. 33:903-905. [PDF]

A. KHWAJA and D. C. LINCH
Haemopoietic growth factors in the treatment of infection in non-neutropenic patients
J. Antimicrob. Chemother. 1994. 33:679-683. [PDF]

ROBERT WILSON and CHARLOTTE RAYNER
Animal models of respiratory infection
J. Antimicrob. Chemother. 1994. 33:381-383. [PDF]

IBRAHIM J. HASSAN
Endophthalmitis—problems, progress and prospects
J. Antimicrob. Chemother. 1994. 33:383-386. [PDF]

J. M. T. HAMILTON-MILLER
Dual-action antibiotic hybrids
J. Antimicrob. Chemother. 1994. 33:197-200. [PDF]

C. S. MCARDLE
Oral prophylaxis in biliary tract surgery
J. Antimicrob. Chemother. 1994. 33:200-202. [PDF]

J.J.S. SNELL
Problems in susceptibility testings—findings of UK NEQAS for microbiology
J. Antimicrob. Chemother. 1994. 33:1-4. [PDF]

R. C. READ and R. G. FINCH
Prophylaxis after splenectomy: J Antimicrob Chemother 1994; 33: 4–6
J. Antimicrob. Chemother. 1994. 33:4-6. [PDF]

JONATHAN WEBER
The molecular basis of anti-retroviral therapy
J. Antimicrob. Chemother. 1993. 32:789-792. [PDF]

A. P. R. WILSON, R. N. GRUNEBERG, and H. NEU
Dosage recommendations for teicoplanin
J. Antimicrob. Chemother. 1993. 32:792-796. [PD